Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 2,334 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PET (Positron Emission Tomography) Clear all

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment; Procedure · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 58
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Encinitas, California + 45 more

Conditions: Prostate Cancer
Interventions: [18F]-DCFPyl Ligand; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Solid Tumors, Cancer
Interventions: HR PEM Scan; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pain
Interventions: Not listed
Lead sponsor: Asokumar Buvanendran; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Positron emission tomography/x-ray computed tomography, Magnetic resonance imaging, x-ray computed tomography (CT); Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 110 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Gainesville, Florida • Miami, Florida

Conditions: PET/CT
Interventions: Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI); Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Glioblastoma
Interventions: MRI-PET, TMZ-PET; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: Brain Scan-PET, Brain Scan-MRI, Arterial Line, Venous Line, Blood Sampling; Procedure
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
Interventions: 177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT, 177Lu whole body (WB) planar and SPECT/CT scans; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Epilepsy, Post-Traumatic
Interventions: [18F]DPA-714 Positron Emission Tomography Scan; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
Interventions: fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging, laboratory biomarker analysis; Radiation · Device · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions: AZD8853, Zirconium-89 crefmirlimab berdoxam; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Surgical Procedure; Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
Interventions: [F-18]RGD-K5; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Irvine, California • Los Angeles, California • Newark, New Jersey + 2 more

Conditions: AML, ALL, MDS, MPD Withou Myelofibrosis, NHL or HL, Inherited Metabolic Disorders, Hemoglobinopathies, Bone Marrow Failure, HLH
Interventions: Clofarabine, Fludarabine, Busulfan, Cyclosporine-A, Mycophenolate Mofetil, Cord Blood Graft; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Progressive Aphasia With Suspected Alzheimer's Disease
Interventions: 18F-AV-1451, PET; Drug · Device
Lead sponsor: University of Chicago; Other
Eligibility: 20 Years to 100 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder, Healthy
Interventions: PET scan, Rolipram; Procedure · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: computed tomography, positron emission tomography; Procedure
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: St Louis, Missouri • Dallas, Texas • Madison, Wisconsin

Conditions: Diabetes Mellitus, Alzheimer Dementia
Interventions: 18F-THK-5351; Drug
Lead sponsor: Columbia University; Other
Eligibility: 55 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET-CT Scan, Questionnaire Administration, Single Photon Emission Computed Tomography; Procedure · Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Sylmar, California • Seattle, Washington

Conditions: Head and Neck Cancer
Interventions: MRI and PET imaging; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System

Additional Positron Emission Tomography (PET) Scan of Brain in Patients Undergoing PET Scan for Diseases Unrelated to Brain

Imaging the Patterns of Breast Cancer Early Metastases

Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)

Bevacizumab w / Temozolomide PET & Vascular MRI For GBM

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

Imaging of CB1 Receptors Using (11C)SD5024

Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer

Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy

PET/MR for Characterization of Renal Masses (RMs)

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Tau PET Imaging in Atypical Dementias

Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients

Positron Emission Tomography Scan and CT Scan in Planning Radiation Therapy for Patients With Stage II or Stage III Non-Small Cell Lung Cancer

TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Functional Imaging of Tumor and Normal Tissue